Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Building upon the results from the CCCG-ALL-2015, CCCG-ALL-2020 multicenter study cohort, concurrent research findings, and the latest clinical trials, the CCCG-ALL-2025 I/HR-B-ALL is thus developed to further improve the event-free survival (EFS), and overall survival (OS), and quality of life (QoL) of children with intermediate- and high- risk B-cell childhood acute lymphoblastic leukaemia (I/HR-B-ALL), while decreasing adverse reactions and transplantation rates. This trial primarily aims to explore: 1. The efficacy of two randomized Blinatumomab application scheme on I/HR-ALL as determined by MRD negatvitiy rate. 2. The efficacy of modified mini-hyperCVD + Venetoclax in I/HR-ALL cannot afford blinatumomab, in contrast to historical control as determined by MRD negatvitiy rate.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek powyżej 1 miesiąca i poniżej 18 lat
- •Rozpoznana ostra białaczka limfoblastyczna na podstawie badania szpiku kostnego
- •Potwierdzony typ B białaczki limfoblastycznej
✗ Disqualifies
- •Białaczka o niskim ryzyku
- •Zespół Downa lub poważne wrodzone choroby genetyczne
- •Wrodzona niedobność odporności lub choroby metaboliczne
- •Wrodzona wada serca z niewydolnością
- •Wcześniejsze leczenie kortykosteroidami przez co najmniej 14 dni lub chemioterapia/radioterapia w ciągu 3 miesięcy przed włączeniem do badania
Simplified criteria — AI translation
Trial details
- Minimum age
- 1 Month
- Maximum age
- 18 Years
- Last updated (source)
- July 23, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (27)
Anhui Medical University Second Affiliated Hospital
Hefei, China
Anhui Provincial Children's Hospital
Hefei, China
Fujian Medical University Union Hospital
Fuzhou, China
Guangzhou Women and Children's Medical Center
Guangzhou, China
Nanfang Hospital, Southern Medical University
Guangzhou, China
The People's Hospital of Guangxi Zhuang Autonomous Region
Nanning, China
The Affiliated Hospital of Guizhou Medical University
Guiyang, China
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China
Wuhan Children's Hospital
Wuhan, China
Hunan Children's Hospital
Changsha, China
The Third Xiangya Hospital of the Central South University
Changsha, China
Xiangya Hospital Central South University
Changsha, China
Nanjing Children's Hospital Affiliated to Nanjing Medical University
Nanjing, China
Children's Hospital of Soochow University
Suzhou, China
Jiangxi Provincial Children's Hospital
Nanchang, China
Qilu Hospital of Shandong University
Jinan, China
Affiliated Hospital of Qingdao University
Qingdao, China
Xi'an Northwest Women and Children Hospital
Xi’an, China
Shenzhen Children's Hospital
Shenzhen, China
West China Second University Hospital, Sichuan University
Chengdu, China
Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC
Tianjin, China
Chongqing Medical University Affiliated Children's Hospital
Chongqing, China
Children's Hospital of Fudan University
Shanghai, China
Shanghai Children's Hospital
Shanghai, China
Shanghai Children's Medical Cener, Shanghai Jiao Tong University School of Medicine
Shanghai, China
Hong Kong Children's Hospital
Hong Kong, Hong Kong
Trial contact
Jingliao Zhang, MD
Xiaofan Zhu, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/24/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.